153
Participants
Start Date
December 27, 2013
Primary Completion Date
November 4, 2019
Study Completion Date
November 4, 2019
Atezolizumab
Atezolizumab will be administered at a fixed dose as specified via IV infusion.
Cobimetinib
Cobimetinib will be administered orally at an escalating dose during Stage 1 and at RP2D during Stage 2.
Peter MacCallum Cancer Centre-East Melbourne, Melbourne
Royal Melbourne Hospital, Parkville
Sloan Kettering Cancer Center; Pediatric Hematology/Oncology, New York
UNC Lineberger Comprehensive Cancer Center, Chapel Hill
SCRI-Tennessee Oncology, Nashville
Texas Oncology, P.A., Arlington
Universitaetsklinikum Freiburg, Freiburg im Breisgau
Rocky Mountain Cancer Center - Denver, Denver
Stanford University Medical Center, Palo Alto
Compass Oncology, Portland
University of Washington Seattle Cancer Care Alliance, Seattle
National University Hospital; Cancer Center, Singapore
Yale University School Of Medicine, New Haven
Massachusets General Hospital Clinical Trial Network and Institute, Boston
Beth Israel Deaconess Med Ctr; Neurology/MS Center, Boston
Princess Margaret Hospital; Department of Med Oncology, Toronto
CHUM Hôpital Notre-Dame, Montreal
Jewish General Hospital, Montreal
"Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden", Dresden
Seoul National University Hospital, Seoul
Asan Medical Center - Oncology, Seoul
Hoffmann-La Roche
INDUSTRY